Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs - Seite 3

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communication, + 33 (0)7 76 99 14 33, [e-mail]
Patricia Sosa Navarro, Chief of Staff to the CEO, [phone], [e-mail]

Investor Relations contacts:

Arthur Stril, Chief Business Officer, [phone], [e-mail]
Ashley R. Robinson, LifeSci Advisors, [phone]

Attachment

• scientific article HSPC_PR_ENGLISH(1)